Yazar "Akdeniz A." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Comparison of propofol and thiopentone during induction in pediatric anaesthesia [COCUKLARDA ANESTEZI INDUKSIYONUNDA PROPOFOL VE TIYOPENTON'UN KARSILASTIRILMASI]
    (1995) Oztekin S.; Ulusoy B.; Akdeniz A.; Ugur G.
    In this study, induction characteristics of propofol (4 mg/kg) were compared with thiopentone (5 mg/kg) in 30 children aged between 5-12 years. Unvoluntary movements were observed in 2 children (% 13) who received propofol in contrast to 1 child (6 %) with thiopentone, although those movements were transient and minor. In the propofol group, the mean duration of apnea was longer than the thiopentone group, which was statistically significant (p<0.05). The arterial blood pressure decreases were more profound in propofol group in comparison with thiopentone group. In conclusion, propofol appears to be a promising alternative to thiopentone in children.
  • Küçük Resim Yok
    Öğe
    Endocarditis-TR: Diagnosis, treatment, and prognosis of the infective endocarditis patients admitting tertiary centres of Turkey
    (Turkiye Klinikleri, 2022) Çalik A.N.; Özlük Ö.A.; Karataş M.B.; Çanga Y.; Eren S.; Ayhan G.; Akdeniz A.
    Background/aim: Infective endocarditis (IE) is still a significant cause of morbidity and mortality among cardiovascular diseases. ENDOCARDITIS-TR study aims to evaluate the compliance of the diagnostic and therapeutic methods being used in Turkey with current guidelines. Materials and methods: The ENDOCARDITIS-TR trial is a multicentre, prospective, observational study consisting of patients admitted to tertiary centres with a definite diagnose of IE. In addition to the demographic, clinical, microbiological, and echocardiographic findings of the patients, adverse events, indications for surgery, and in-hospital mortality were recorded during a 2-year time interval. Results: A total of 208 IE patients from 7 tertiary centres in Turkey were enrolled in the study. The study population included 125 (60.1%) native valve IE (NVE), 65 (31.3%) prosthetic IE (PVIE), and 18 (8.7%) intracardiac device-related IE (CDRIE). One hundred thirty-five patients (64.9%) were culture positive, and the most frequent pathogenic agent was methicillin-susceptible Staphylococcus aureus (MSSA) (18.3%). Among 155 (74.5%) patients with an indication for surgery, only 87 (56.1%) patients underwent surgery. The all-cause mortality rate was 29.3% in-hospital follow-up. Multivariable Cox regression analysis revealed that absence of surgery when indicated (HR: 3.29 95% CI: 0.93–11.64 p = 0.05), albumin level at admission (HR: 0.46 95% CI: 0.29–0.73 P < 0.01), abscess formation (HR: 2.11 95% CI: 1.01–4.38 p = 0.04) and systemic embolism (HR: 1.78 95% CI: 1.05–3.02 p = 0.03) were ascertained independent predictors of in-hospital all-cause mortality. Conclusion: The short-term results of the ENDOCARDITIS-TR trial showed the high frequency of staphylococcal IE, relatively high in-hospital mortality rates, shortage of surgical treatment despite guideline-based surgical indications and low usage of novel imaging techniques. The results of this study will provide a better insight to physicians in respect to their adherence to clinical practice guidelines. © TÜBİTAK.
  • Küçük Resim Yok
    Öğe
    The role of azacitidine in the treatment of elderly patients with acute myeloid leukemia: Results of a retrospective multicenter study [Akut miyeloid lösemili yaşlı hastaların tedavisinde azasitidinin rolü: Retrospektif çok merkezli bir çalışmanın sonuçları]
    (Turkish Society of Hematology, 2016) Tombak A.; Uçar M.A.; Akdeniz A.; Tiftik E.N.; Şahin D.G.; Akay O.M.; Yıldırım M.; Nevruz O.; Kis C.; Gürkan E.; Solmaz Ş.M.; Özcan M.A.; Yıldırım R.; Berber İ.; Erkurt M.A.; Tuğlular T.F.; Tarkun P.; Yavaşoğlu İ.; Doğu M.H.; Sarı İ.; Merter M.; Özcan M.; Yıldızhan E.; Kaynar L.; Mehtap Ö.; Uysal A.; Şahin F.; Salim O.; Sungur M.A.
    Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of ?60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (?5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA. © 2016, Turkish Society of Hematology. All rights reserved.